CVS Health (NYSE:CVS) Q4 2025 Earnings call February 10, 2026 08:00 AM ET Company ParticipantsAndrew Mok - Director of Equity ResearchBrian Newman - CFODavid Joyner - Chairman and CEOEdward DeVaney - EVP and PresidentLawrence McGrath - EVP of Capital MarketsLisa Gill - Managing DirectorPrem Shah - Chief Pharmacy Officer and President of Pharmacy and Consumer WellnessSree Chaguturu - EVP and President of Healthcare DeliverySteve Nelson - EVP and President of AetnaConference Call ParticipantsAnn Hynes - Equit ...

Summary of Claritev (NYSE:CTEV) FY Conference Call Company Overview - **Company Name**: Claritev (formerly MultiPlan) - **Industry**: Healthcare technology and services - **Key Executives**: Travis Dalton (President and CEO), Doug Garis (CFO) Core Points and Arguments Company Vision and Strategy - Claritev focuses on transparency and affordability in healthcare, emphasizing clear insights around pricing for employers managing risk and employee benefits [1][2] - The company serves over 700 payer clients and has a provider network of 1.4 million, which is considered a key asset that has been underinvested in [2][3] - The leadership aims to build a sustainable growth company rather than engage in financial engineering, focusing on long-term value creation [4][5] Financial Performance - The company reported a stock increase of 180%-190% year-over-year, indicating strong market performance [3] - In Q3, revenue grew by 7% with record EBITDA, marking the strongest revenue print in absolute dollar terms over the last 12 quarters [26][27] - The company has invested significantly in technology, with $500 million spent over five years and an additional $100 million planned for technology transformation [28] Technology and Innovation - Claritev is transitioning to Oracle Cloud, enhancing its technology infrastructure and enabling faster product development, such as the Network Builder tool [9][50] - The company is focused on integrating AI into its workflows to improve efficiency and service delivery [32] - New product launches and enhancements are planned, with over 30 solution enhancements and 10 new products expected this year [22] Market Position and Growth Opportunities - The company is well-positioned to address challenges in the healthcare market, including cost inflation and regulatory changes, with products that enhance affordability and transparency [8][9] - Claritev's revenue model is based on a percentage of savings (P-save), making it a sticky and profitable business [28][29] - The company is expanding its addressable market by selling existing products into new verticals and international markets without significant customization [19][20] Client Relationships and Sales Strategy - A new client success organization has been established to enhance service for existing clients, leading to multi-year renewals for top clients [44][46] - The sales pipeline has grown significantly, with over 20 new logos acquired in the first three quarters of the previous year [40] Future Outlook - The leadership emphasizes a focus on execution in 2026, aiming for strong financial growth and product innovation [53][54] - Employee satisfaction and engagement are also key focuses, with the belief that a committed workforce will drive long-term success [55][56] Additional Important Content - The company has a high provider acceptance rate, with over 90% of transactions proceeding smoothly [23][24] - Claritev's competitive advantage lies in its extensive data rights agreements and custom business rules developed over years of service [23] - The leadership team has been restructured to enhance focus and drive growth, with a commitment to transparency and accountability in operations [39][42]

Group 1 - President Trump plans to convene major health insurance companies to pressure them into lowering healthcare costs for Americans facing premium increases after the expiration of ObamaCare subsidies [1][2] - The meeting is expected to take place in the coming weeks, with Trump emphasizing the need for insurance companies to reduce their profits significantly [2][3] - The health insurance industry, represented by AHIP, stated that premiums reflect healthcare costs and that insurance companies are doing their best to protect Americans from rising medical expenses [2][3] Group 2 - Over 20 million Americans are projected to see their healthcare premiums double by 2026, which could strain middle and low-income voters already concerned about living costs [3] - The Democratic Party is focusing on the rising premiums as a key issue for voters, especially in light of the upcoming midterm elections [3] - Trump's public pressure on insurance companies may create uncertainty regarding future profit margins and rates, negatively impacting the valuation of the health insurance sector in the short term [3] Group 3 - Trump announced agreements with nine pharmaceutical companies to lower drug prices for low-income and disabled individuals, claiming it as a significant victory for patients [4] - The agreements include commitments to sell discounted drugs directly to consumers and to launch new drugs in the U.S. at prices comparable to those in overseas markets [4] - Trump expressed optimism that these measures would lead to a rapid decrease in drug prices, potentially making them the lowest among developed countries [4]

Financial Data and Key Metrics Changes - For Q3 2025, the company reported revenue of $1.44 billion, a slight decrease from $1.45 billion in Q3 2024. The medical margin was negative $57 million, compared to negative $58 million in the same period last year. Adjusted EBITDA was negative $91 million, an improvement from negative $96 million in Q3 2024 [4][17][19] - The company reinitiated its 2025 guidance, expecting revenue between $5.81 billion and $5.83 billion, with a medical margin projected between negative $5 million and negative $15 million, and adjusted EBITDA guidance ranging from negative $270 million to negative $245 million [6][22][23] Business Line Data and Key Metrics Changes - Medicare Advantage membership at the end of Q3 2025 was 503,000, down from 525,000 in Q3 2024. ACO REACH membership decreased to 115,000 from 132,000 in the same period [17] - The company experienced a negative impact of $20 million from exited markets during the quarter [18] Market Data and Key Metrics Changes - The company noted that the 2025 risk adjustment scores were lower than expected, impacting revenue by approximately $150 million for the full year. This was primarily driven by one payer in a new market [18] - The company expects to end 2025 with approximately $310 million in cash, including about $65 million held off-balance sheet by ACO entities [23][28] Company Strategy and Development Direction - The company is focused on executing strategic initiatives aimed at improving contract economics, reducing risk, and optimizing cost structures. It anticipates a $30 million reduction in operating expenses for 2026 [16][24] - The company is taking a disciplined approach to payer contracting, which includes reducing Part D exposure and enhancing quality incentives [9][26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, citing several tailwinds such as a 9% benchmark rate increase and better-aligned payer contracts. They believe these factors will drive material improvement in performance [24][25] - The leadership team is actively engaged in improving performance and is committed to enhancing Agilon's position for sustainable value creation [15][29] Other Important Information - The company is currently in the process of searching for a new CEO, with a focus on candidates who align with the company's new strategic direction [15][36] - The company plans to pursue a reverse stock split and seek stockholder approval at the annual general meeting in 2026 [28] Q&A Session Summary Question: Impact of ACO REACH changes on EBITDA - Management acknowledged that changes to the ACO REACH program would lead to lower economics but still contribute positively to margins. They are reviewing ACOs to determine better models for 2026 [30][31] Question: Potential market exits and payer contracts - Management confirmed a disciplined approach to contracting, indicating that they would not engage with payers if the economics do not make sense. Any reduction in membership would benefit medical margins and EBITDA [32][33] Question: Update on CEO search - The search for a new CEO is ongoing, with good candidates emerging. Management emphasized active engagement in improving business performance during this transition [35][36] Question: Medical cost trends in Q3 - Management noted that inpatient and Part B oncology drug costs remain high, but overall medical cost trends have restated favorably [36] Question: Cash allocation to ACO REACH entities - The company clarified that there is no minimum cash requirement for ACO REACH entities, but maintaining cash there provides tax efficiencies [37] Question: Changes in provider contracts - Management stated that there are no significant changes to provider contracts, but they are aligning incentives with physician partners to achieve operating savings [45][46] Question: Impact of Humana's focus on benefit stability - Management indicated that they analyze benefit designs from all payers, including Humana, as part of their contracting process [52][53]